Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
Authors:
Open Access
- 5 January 2019
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 10 (1) , 215-228
Abstract
Introduction To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM). Methods Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks. The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI). The secondary end points were changes in body weight (BW), glucose variability, diabetes treatment satisfaction questionnaire (DTSQ) score, and eating behavior. Results There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment. Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment. However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating. The DTSQ score for “convenience” improved in the dulaglutide group. No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups. Conclusion We showed that once-weekly dulaglutide was comparable to once-daily liraglutide in terms of oxidative stress and endothelial function. Switching from liraglutide to dulaglutide improved convenience by decreasing the number of injections without deteriorating glucose metabolism. Trial Registration This trial was registered with the University Hospital Medical Information Network (UMIN no. 000034353) on 10 October 2018.Keywords
This publication has 31 references indexed in Scilit:
- Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot studyDiabetes Research and Clinical Practice, 2018
- Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetesDiabetes Research and Clinical Practice, 2016
- Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental databasePatient Preference and Adherence, 2016
- Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in J apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III studyDiabetes, Obesity and Metabolism, 2016
- Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with Type 2 DiabetesCardiovascular Diabetology, 2012
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007
- The Burden of Mortality Attributable to DiabetesDiabetes Care, 2005
- The post-prandial state and cardiovascular disease: relevance to diabetes mellitusDiabetes/Metabolism Research and Reviews, 2000
- A simple test to monitor oxidative stress.1999